## Characteristics of Cerebrospinal Fluid in Autism Spectrum Disorder - A Systematic Review

Vandana Srivastavaa-c, Christian O'Reillya-d

<sup>a</sup> Al Institute, University of South Carolina, 5th floor, 1112 Greene St., Columbia, South Carolina, USA.

- <sup>b</sup> Department of Computer Science and Engineering, University of South Carolina, Columbia, South Carolina, USA.
- ° Carolina Autism and Neurodevelopment Research Center, University of South Carolina,

Columbia, South Carolina, USA.

<sup>d</sup> Institute for Mind and Brain, University of South Carolina, Columbia, South Carolina, USA.

Correspondence: Vandana Srivastava, vandana@email.sc.edu

# **Declaration of interest: none**

## Abstract

Autism Spectrum Disorder (ASD) is a range of neurodevelopmental conditions characterized by impaired social interaction, learning, and restricted or repetitive behaviors. The underlying causes of ASD are still debated, but researchers have found many physiological traits to help understand the etiology of ASD. Some of the features that characterize people with ASD are immune markers (e.g. increased lymphocytes, cytokine levels), decreased neuropeptides like oxytocin and arginine vasopressin, folate deficiency, change in brain anatomy and physiology, and increased extra axial cerebrospinal fluid (CSF). CSF has a critical role in maintaining the homeostasis of the neuronal environment and has, therefore, been analyzed in multiple conditions that impact the central nervous system. The study of CSF is critical in understanding neurological disorders as its composition changes with the disorders, and these changes may indicate various disorder-related physiological mechanisms. For this systematic review, we searched the PubMed database for studies published between 1977 and 2023. We found 54 studies from 276 eligible for this review after manual screening. We took stock of the evidence supporting the hypothesis that ASD alters the properties and composition of CSF. We systematically report on the different attributes of CSF in the ASD population that could 1) be potential biomarkers, 2) assist in understanding the origins and progression of ASD, and 3) shed light on the aspects of the relationship between ASD and the immune system.

Keywords: autism spectrum disorder, cerebrospinal fluid, immune system,

# Introduction

Autism Spectrum Disorder (ASD) is a complex neurodevelopment disorder that results in an array of challenges associated with social interactions, communication skills, learning, and repetitive behaviors. Individuals with ASD may present varying degrees of impairment, etiology, and phenotypical profile. Hence, this condition is referred to as a "spectrum" disorder. According to the Centers for Disease Control and Prevention, the prevalence of ASD among children aged 8 years in the USA was 1 in 36 (2.8%; approximately 4% of boys and 1% of girls) in 2020 (CDC, 2022). Factors contributing to the etiology of ASD are diverse and not all fully ascertained but many studies have been carried out to determine the anatomical and physiological characteristics specific to the ASD population. Analyzing the properties of the cerebrospinal fluid in that population is one of the avenues that have been investigated to gain a deeper understanding of ASD.

The cerebrospinal fluid, or CSF, is a clear, colorless fluid present in the region surrounding the brain and spinal cord of vertebrates (Adigun, Al-Dhahir, 2022). It serves multiple purposes, including keeping the brain floating, cushioning it from jolts and preventing associated trauma, helping distribute various substances between brain cells, and carrying away the waste produced from neural activity. The CSF is found in the brain ventricles and the cranial and spinal subarachnoid space. It is produced mostly by the neuroepithelial lining (called *ependyma*) of the brain ventricular system (Jiménez et al., 2014) and the central canal of the spinal cord. These special ependymal cells exist in the choroid plexus (CP), an organ that facilitates the entry of immune cells into the central nervous system (CNS) and monitors the synthesis, formation, and flow of CSF (Lun et al., 2015). The brain interstitial fluid and capillaries also secrete a small amount of CSF (Sakka et al., 2011).

The CSF is regenerated about 4-5 times per day. It is similar in composition to blood plasma except that it contains negligible proteins and has higher concentrations of Na<sup>+</sup>, Cl<sup>-</sup>, and Mg<sup>+</sup>, and lower concentrations of K<sup>+</sup> and Ca<sup>2+</sup> (Sakka et al., 2011). Monoamines like dopamine, serotonin, melatonin, and neuropeptides like atrial natriuretic peptide (ANP) play an important role in CSF regulation (Faraci et al., 1990). Along

3

with monoamines and neuropeptides, arginine vasopressin (AVP) receptors are present on the surface of the choroidal epithelium. CSF secretion is found to be decreased by ANP and AVP (Faraci et al., 1990).

CSF is easy to obtain and can be drawn from the spinal canal at very low risk. Because of its proximity to CNS, the white blood counts, protein levels, serum-glucose ratio, and other properties of the CSF can help differentiate CNS infections caused by distinct pathogens (Gomes, 2022), making it an important medical diagnostic tool. The circulation of CSF can also be determined non-invasively using Magnetic Resonance Imaging (MRI). The study and interpretation of CSF is critical to understand neurological disorders as its composition, quantity, and flow, changes with the disorders. (Hrishi & Sethuraman, 2019).

With this review, we aim to synthesize the knowledge gathered from previous studies to clarify if and how ASD is associated with changes in the properties of the CSF. More specifically, we aim to thoroughly assess the evidence supporting the hypothesis that the composition and properties of the CSF are altered in ASD, compared to neurotypical individuals.

## Method

The search strategy followed the PRISMA guidelines (Fig 1). PubMed database was queried with the research string (*"cerebrospinal fluid" or csf) and ("Autism" or "ASD"*) not diet not schizo\* not antisiphon not hydrocep\* to filter the studies related to schizophrenia, hydrocephalus, and antisiphon devices. The PubMed was last queried in January 2024 and included papers (total 272) that were published between 1977 and December 2023. The criteria for choosing the papers were:

- 1. CSF was analyzed in the context of ASD.
- The paper was not a neuroimaging study, except when the focus was to characterize extra-axial CSF.
- 3. The paper was not a review or meta-analysis.

The papers were manually reviewed and screened by the first author (VS). Problematic cases were discussed or independently reviewed by the senior author (COR). Out of 272, only 50 fulfilled the selection criteria and are considered for this review. We also included 4 other research papers that were

not returned in the search results but were found by following the references of reviewed papers and are closely aligned with the aim of this review. The following data were collected from the studies:

- Author and year (column 1)
- Age of both study group (ASD participants) / control group (non-ASD or neurotypical) (column 2)
- Size of the study group (count of ASD participants whose CSF is analyzed) (column 3)
- Sex distribution (number of males and females) in the study group (column 3)
- Size of the control group (count of non-ASD or neurotypicals whose CSF is analyzed) (column 4)
- Sex distribution (number of males and females) in control group (column 4)
- Observation (CSF characteristic in the study group as compared to the control group) (column 5)

We manually collected the data from each study from the "abstract" and "results" sections and organized it in tabular form. We have used dashes (-) to denote missing values in the age/size column. To avoid bias, we also included studies with null results.



Fig 1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart describing the paper selection process.

### Results

A total of 54 papers were studied to find the characteristics of CSF in ASD. We organized the papers into seven categories based on their observed CSF properties. The categories are:

- 1. Immune markers
- 2. Extra-axial CSF
- 3. Folate deficiency
- 4. Protein / amino acid
- 5. Monoamine neurotransmitters (serotonin, dopamine)

- 6. Nanopeptides (oxytocin, arginine vasopressin)
- 7. Others (beta-endorphin, gangliosides)

Two studies (Ramaekers et al., 2020) and (Young et al., 1977) were mentioned in two different tables

("monoamine neurotransmitters", "folate deficiency") and ('immune markers", "folate deficiency"),

respectively. Fig 2 shows the distribution of research papers in each category.

The body of literature reviewed is biased concerning age and sex. Most of the studies included either only

males or a large number of males in their research. Also, most human studies were conducted with infants

or children, with very few studies in adults.



Fig 2: Distribution of research papers in each category.

# Presence of neuroinflammation markers in CSF

Many comorbidities of ASD indicate an altered immune system, including allergies (Xu et al., 2018), gastrointestinal issues (Saurman et al., 2020), and autoimmune diseases (Hughes et al., 2018). These comorbid conditions add to the ASD burden, often resulting in poorer quality of life. The molecular properties of CSF change during inflammation and disease of the CNS (Świderek-Matysiak et al., 2023). In a neuro-inflammatory study (Lepennetier et al., 2019), the CSF and serum of 75 subjects was tested for 36 cytokines (CCL1–3, CCL7, CCL8, CCL11, CCL13, CCL19, CCL20, CCL22–27, CXCL1, CXCL2, CXCL5, CXCL6, CXCL8, CXCL9, CXCL11–13, CXCL16, CX3CL1, IL-2, IL4, IL-6, IL-10, IL-16, GM-CSF, IFN-γ, MIF, TNFα, and MIB1β). The authors observed that 26 out of 36 cytokine levels were increased compared to the control group. Also, CSF cytokine concentrations were positively correlated with CSF

immune cell counts (CD4 and CD8 T cells, B cells, plasmablasts, monocytes, and NK-natural killer cells) (Lepennetier et al., 2019). Inflammatory molecules have been shown to impact neurodevelopment, and early-life inflammation has been linked with neurodevelopmental disorders like ASD cerebral palsy, epilepsy, and schizophrenia (Jiang et al., 2018). In ASD, a significant increase in proinflammatory cytokines and growth factors was found, especially the chemokine MCP-1 (12-fold increase) (Vargas et al., 2005). MCP-1 is a chemokine that is associated with innate immune reactions and is vital for monocyte and T-cell activation in regions of tissue injury (Vargas et al., 2005). In a postmortem study of ASD, the lymphocytes were increased in white and gray matter tissues of most brain regions for ~65% of participants with ASD as compared to controls (DiStasio et al., 2019), irrespective of age and sex.

Growth factors play a regulatory role in immune and vascular systems (Pardo et al., 2017). In a longitudinal study, a significant difference was found in CSF growth factors EGF and sCD40L (Pardo et al., 2017) in children (2 to 8 years of age) with ASD compared to controls. EGF is important for the growth, proliferation, and differentiation of numerous cell types and is involved in several pathways of neuronal function, whereas sCD40L modulates the function of B cells (Pardo et al., 2017). The CSF profiles of cytokines, chemokines, and growth factors did not change significantly in the follow-up performed 1.17 to 3.53 years later (Pardo et al., 2017). The same study found decreased levels of quinolinic acid, which indicates the inefficiency of kynurenine pathway to form quinolinic acid from tryptophan (Zimmerman et al., 2005). Decreased neopterin in CSF with increased biopterin suggested that the neuroinflammation in the subjects of this study was not due to the metabolic pathways (Zimmerman et al., 2005).

Tumor necrosis factor-alpha (TNF- $\alpha$ ) is an inflammatory cytokine produced by macrophages/monocytes during severe inflammation (Idriss & Naismith, 2000) and its elevation is associated with several autoimmune diseases like rheumatoid arthritis, crohn's disease, and psoriasis (Parameswaran & Patial, 2010). The presence of inflammation and immune system over-activation in ASD is supported by reports of elevated levels of TNF- $\alpha$  in the CSF of an all-male cohort (Chez et al., 2007). Another study found elevated levels of TNF- $\alpha$  in the serum but not the CSF of a group of participants with ASD (Zimmerman et

8

al., 2005). However, this study reported no significant correlation between the level of TNF- $\alpha$  in serum and CSF, and the use of small sample sizes may be responsible for non-conclusive tests. Presence of neuroinflammation is further supported by a recent study that found elevated levels of TNF- $\alpha$  and interleukins (Than et al., 2023) in ASD.

Despite immune dysregulation in ASD, initial studies found CSF immunoglobulin (antibodies) levels in the normal range in the ASD cohort when compared with previous studies (Young et al., 1977). Table 1 summarizes the studies related to immune markers in CSF.

|   | Age (study<br>group /<br>control<br>group) | Study group<br>(ASD<br>participants)         | Control group<br>(Non-ASD<br>participants) | Observations (in the study group)  |  |
|---|--|--|--|--|--|
| Than et al.<br>2023   | 3 - 11 years /<br>1 - 18 years             | 26 (-)                                       | 8 (-)                                      | Significantly increased TNF- $\!\alpha$ , IL-4, IL-21 levels in CSF  |  |
| DiStasio et<br>al. 2019   | 5 - 68 years /<br>1 - 64 years             | 25<br>postmortem<br>(19 males, 6<br>females) | 30 postmortem (19<br>males, 11 females)    | Increased lymphocytes in ~65% of males and<br>females, across all ages, in most brain regions,<br>white/gray matter, and leptomeninges; more CD3 <sup>+</sup> T<br>lymphocytes than CD20 <sup>+</sup> B lymphocytes and CD8 <sup>+</sup><br>than CD4 <sup>+</sup> T lymphocytes  |  |
| Pardo et<br>al. 2017  | 2 - 8 years                                | 67 (55 males,<br>12 females)                 | 54 (41 males, 13<br>females)               | Significant differences in the growth factors in the<br>CSF of the ASD group with respect to controls;<br>profiles of cytokines, chemokines, and growth<br>factors did not change significantly in ASD in the<br>follow-up years   |  |
| Chez et al.<br>2007   | 2.5 - 9.7<br>years                         | 10 males                                     | Compared with previous studies             | CSF TNF- $\alpha$ was significantly increased in comparison to serum-TNF- $\alpha$   |  |
| Zimmerman<br>et al. 2005  | 2.7 - 10<br>years / 2-<br>14 years         | 12 (10 males,<br>2 females)                  | 15 (6 males, 9<br>females)                 | Elevated levels of $TNF-\alpha$ in the serum but not the CSF of the autism group; quinolinic acid and neopterin were decreased, and biopterin was elevated in autism group   |  |
| Vargas et al.<br>2005   | 3 - 10 years /<br>12 - 45 years            | 6 (4 males, 2<br>females)                    | 9 (3 males, 6<br>females)                  | Significantly increased MCP-1(12-fold increase); no differences in expression of TARC or TGF- $\beta$ 1; increased cytokines (IL-6, IFN- $\gamma$ , IL-8, MIP1 $\beta$ , NAP-2, IFN- $\gamma$ inducing protein-10) and angiogenin; increased growth factors (MIF, VEGF, LIF, osteoprotegerin, HGF, PARC, FGF-4, FGF-9, IGFBP3, and IGFBP4) |  |
| Young et al.<br>1977  | 3.8 – 9.1<br>years / -                     | 15 (11 males,<br>4 females)                  | Compared with<br>previous studies          | CSF immunoglobulin levels were within normal limits  |  |
| Abbreviations- TNF: Tumor necrosis factor, MIF: Mesoderm inducing factor, VEGF: Vascular endothelial growth factor, |  |  |  |  |  |

## Table 1: Immune markers in CSF

Abbreviations- TNF: Tumor necrosis factor, MIF: Mesoderm inducing factor, VEGF: Vascular endothelial growth factor, TGF-β1: Tumor growth factor–β1, NAP-2: Neutrophil activating peptide-2, TARC: Thymus and activation regulated chemokine, FGF: Fibroblast growth factor, IGFBP: Insulin-like growth factor binding protein LIF: Leukemia inhibitory factor, HGF: Hepatic growth factor, BDNF: Brain-derived neurotrophic factor, MCP-1: a chemokine, MIP1β: Macrophage inflammatory protein-1β, IFN–γ: Interferon—gamma, IL: Interleukin

#### Extra axial CSF in infants later diagnosed with ASD

The presence of increased CSF volume in the subarachnoid space surrounding the cortical surface is a brain abnormality referred to as extra axial cerebrospinal fluid (EA CSF). Having a large volume of CSF forces the ventricles to widen, causing pressure on brain tissues. This can eventually lead to brain damage. Many studies have confirmed that children later diagnosed with ASD had EA CSF from 6 to 24 months compared to neurotypicals (Hallahan et al., 2009; McAlonan et al., 2005; Shen, 2018; Shen et al., 2018; Shen & Piven, 2017). Excess CSF has been associated with an enlargement of the head circumference in ASD (Denier et al., 2022; Shen et al., 2013, 2018). EA-CSF has also been linked with enlargement of the perivascular spaces (fluid-filled channels that surround blood vessels in the brain) from 6 to 24 months in ASD, leading to sleep problems later in ages between 7 - 12 years (Garic et al., 2023). The amount of EA CSF at 6 months has also been claimed to be predictive of later ASD symptom severity (Shen et al., 2013). CSF volume was reported to stabilize before 4 years of age (Peterson et al., 2021). No significant difference in CSF volume was found for adults in one study (Creasey et al., 1986), although a different study reported subarachnoid CSF/meningeal CSF volume to be significantly different in ASD compared to controls in a male-only cohort of mean age 15 years (Tate et al., 2007). Finally, a study involving proband-sibling pairs (i.e., infants at elevated likelihood for ASD given the presence of an older sibling with a diagnosis of ASD) found the brain size of the younger siblings to be correlated with the scores on the Social Communication Questionaries of the older proband sibling in the groups where the younger sibling was diagnosed with ASD at 24 months but found no such association for EA CSF at 6, 12, or 24 months (Girault et al., 2022).

The results for the relationship between EA CSF and ASD are summarized in Table 2.

# Table 2: Extra-axial CSF

|   | Age (study<br>group /<br>control<br>group)               | Study group (ASD participants)  | Control group (Non-<br>ASD participants) | Observations (in the study group)  |  |
|---|--|---|--|--|--|
| Garic et al.<br>2023  | 6.5, 12.7, 24.7<br>months / 6.7,<br>12.6, 24.7<br>months | 47 (ELA; ASD+; 40<br>males, 7 females)<br>180 (ELA; ASD-; 102<br>males, 78 females) | 84 (TLA; ASD-; 55<br>males, 29 females)  | Across all groups, enlarged PVS at 24<br>months was associated with greater EA<br>CSF volume from ages 6 to 24 months and<br>more frequent night wakings at school-age |  |
|   | 6 months   | 42 ELA; ASD+  | 149 ELA; ASD-                            | no significant association between proband   |  |
| Girault et al.  | 12 months  | 39 ELA; ASD+  | 182 ELA; ASD-                            | autistic traits (SCQ score) and sibling EA   |  |
| 2022  | 24 months  | 42 ELA; ASD+ 159 ELA; ASD-  |  | ASD+ and ASD- groups)  |  |
| Denier et al.<br>2022   | >=20 years   | 120 (all males)   | 136 (all males)                          | Increased head circumference due to EA-<br>CSF   |  |
| Peterson et<br>al. 2021   | 3 - 42 years   | 97 (all males)  | 92 (all males)                           | No difference in EA CSF volume between ASD and neurotypical  |  |
| Shen et al.<br>2018   | 2 - 4 years  | 159<br>(132 males, 27<br>females)   | 77<br>(49 males, 28 females)             | ASD group had an average of 15.1% more<br>EA CSF than controls; enlarged head<br>circumference in the ASD group  |  |
| Shen et al.<br>2017   | 6 - 24 months  | 221 ELA (47 ASD+)   | 122 TLA                                  | Elevated levels of EA CSF in ELA group<br>than TLA;18% more EA CSF at 6 months in<br>ELA ASD+ than in the ELA group  |  |
|   | 6 - 9 months   | 33 ELA (22 males, 11 females) (10 ASD+)   | 22 TLA (15 males, 7 females)             | Significantly elevated EA CSF in ELA   |  |
| Shon et al  | 1 - 1.2 years  | 27 ELA  | 16 TLA                                   | infants at 6-9 months and continued until  |  |
| 2013  | 1.5 - 2 years  | 26 ELA  | 16 TLA                                   | months was predictive of the severity of<br>ASD symptoms; enlarged brain at an early<br>age  |  |
| Hallahan et<br>al. 2009   | Mean age:<br>18 years /<br>32 years                      | 114 (96 males, 18<br>females)   | 60 (53 males, 7<br>females)              | Significantly larger volume of peripheral CSF in ASD than controls   |  |
| Tate et al.<br>2007   | Mean age<br>14.7 years /<br>13.6 years                   | 34 males  | 26 males                                 | Significantly different relationship between<br>subarachnoid CSF/meningeal volume than<br>controls   |  |
| McAlonan<br>et al. 2005   | 12 ± 1.8 years<br>/ 11 ± 1.2<br>years                    | 17 (16 males, 1<br>female)  | 17 (16 males, 1<br>female)               | Increased total CSF volume   |  |
| Creasey et<br>al. 1986  | 18 - 39 years /<br>21 - 37 years                         | 12 males  | 16 males                                 | No significant difference in volume of CSF   |  |
| Abbreviations- ASD+: later diagnosed with ASD, ASD-: later diagnosed without ASD, ELA: Elevated likelihood for ASD,<br>EA CSF: Extra axial cerebrospinal fluid. TLA: Typical likelihood for ASD. PVS: Perivascular spaces |  |   |  |  |  |

# Low folate level in CSF

Folate is a vitamin (B9) essential for brain health. It supports the creation of DNA and RNA, the formation

of neurotransmitters, and the development of the nervous system during pregnancy (Balashova et al.,

2018; Gordon, 2009). The predominant form of folate in cerebrospinal fluid is 5-Methyl-tetra-hydrofolate

(5-MTHF). Cerebral folate deficiency (CFD) is caused by the malfunction in the folate receptor alpha (FRA), a protein that binds to folate (Gordon, 2009). FRA is created in the choroid plexus localized within the border of the cerebral ventricles and moves into the CSF (also released by the choroid plexus) to be transported to the brain. CFD can be caused by the presence of FRA autoantibodies that interfere with the function of that receptor.

The earliest study (Lowe et al., 1981) conducted on autistic and non-autistic neuropsychiatric patients found the CSF folate levels to be within the normal range in both groups. The subset of patients in the autistic group who were given oral folic acid supplements did not show clinical improvements (Lowe et al., 1981). Similarly, a more recent longitudinal study (two time points separated by 1-3 years) exploring the association between CFD and autism found no significant correlation between CSF 5-MTHF levels and autistic features (Shoffner et al., 2016). However, a few studies found low CSF 5-MTHF in ASD (Frye et al., 2013; Moretti et al., 2005; Ramaekers et al., 2007) and proposed oral *d,I-leucovorin (folinic acid)* (Moretti et al. 2005; Ramaekers et al. 2007; Frye et al. 2013) to alleviate ASD associated symptoms. In some cases (Frye et al., 2013, 2020; Moretti et al., 2005; Ramaekers et al., 2007) oral folic acid improved verbal communication, motor skills, and CSF 5-MTHF levels in the ASD group. Frye et al (2013) reported the presence of FRA in 75.3% (70/93) of the ASD group. A recent study found the CSF to have low folate in only 21% (8/38) of ASD participants when compared to controls (Ramaekers et al., 2020). Table 3 summarizes the CSF folate deficiency papers in ASD.

|                           | Age (study<br>group /<br>control group)   | Study group<br>(ASD<br>participants) | Control group<br>(Non-ASD<br>participants)    | Observations (in the study group)  |
|---------------------------|---|--------------------------------------|---|--|
| Ramaekers et<br>al., 2020 | 3.6 – 18 years<br>/ 4.4 - 16 years        | 38 (31 males, 7<br>females)          | 24 (12 males, 12<br>females)                  | Low MTHF in 21% participants   |
| Shoffner et al.,<br>2016  | 2 - 6 years,                              | Visit 1: 67                          |   | CSF 5-MTHF levels vary significantly over time in  |
|                           | 3.5 - 9.5 years<br>/<br>2 - 10 years      | Visit 2: 31 (1-3<br>years later)     | 140   | an unpredictable way; no significant relationship to clinical features of autism   |
| Frye et al.,<br>2013      | 2.9 - 17.4<br>years                       | 93 (84 males, 9<br>females)          | 44 treated with<br>leucovorin<br>26 untreated | High prevalence (75.3%) of FRA; low CSF 5-<br>MTHF; 44 children were given leucovorin calcium<br>tablets; improvement in 44 treated vs. 26 untreated<br>children on ratings of verbal communication,<br>receptive and expressive language, attention |
| Ramaekers et al., 2007    | 2.8 - 12.3<br>years / 3.3 -<br>11.4 years | 25 (18 males, 7<br>females)          | 25 (14 males, 11<br>females)                  | CSF 5-MTHF was low in 23/25 (92%) in ASD; oral folic acid supplements led to normal CSF 5-MTHF   |
| Moretti et al.,<br>2005   | 6 years                                   | Case report: 1<br>female             | -   | Low CSF 5-MTHF; treatment with folinic acid<br>resulted in improved CSF 5-MTHF concentration<br>and better motor skills  |
| Lowe et al.,<br>1981      | 4 - 22 years /<br>2 - 32 years            | 16                                   | 19  | CSF folate levels were within the normal range in<br>both ASD and control group  |
| Young et al.<br>1977      | 3.8 – 9.1 years<br>/ -                    | 15 (11 males, 4<br>females)          | Compared with<br>previous studies             | CSF folate levels were within normal limits  |

## Table 3: Folate levels in CSF

Abbreviations- FRA: Folate receptor autoantibodies, MTHF: Methyl-tetra-hydrofolate

# Changes in the CSF protein levels

Amino acids are molecules that combine to form proteins. These proteins serve many cellular functions. A large proportion of proteins in the normal CSF is derived from blood, e.g., albumin which constitutes 35 - 80% of total protein in CSF. About 20% of the proteins in CSF are produced in the brain by neurons, glial cells, and leptomeningeal cells (Reiber, 2003). Changes in the brain-derived CSF protein concentration may indicate CNS disorder, impaired blood-brain barrier, or disruption in CSF flow (Reiber, 1994, 2003; Schilde et al., 2018; Wichmann et al., 2021). The CSF analysis in ASD found altered levels of albumin and several proteins. In adults with ASD, the overall protein concentration and albumin quotient (ratio of CSF and serum albumin (Andrews et al., 1994)) were found to be increased (Runge et al., 2020). An elevated concentration of ethanolamine (Perry, 1978) suggested CNS abnormality in ASD.

STAT3 is a protein activated by ischemic or traumatic injury in the brain (Dziennis & Alkayed, 2008). In a rat model of autism, the STAT3 protein was found to be significantly elevated in CSF (Khera et al., 2022).

Long-term treatment with Guggulsterone (GST), a plant-derived extract used as an antidepressant, improved locomotor activity, memory, depressive behavior, and STAT3 levels in this animal model (Khera et al., 2022).

Astrocytes are glial cells that ensure the defense and support of CNS during development, across adulthood, and in aging. Glial fibrillary acidic protein (GFAP) and S-100 are two of the many proteins expressed in astrocytes, that provide strength to glial cells and maintain blood-brain barrier (Kuroda, 1983). In response to brain injury or other neuro-damaging conditions, astrocytes trigger processes (reactive astrogliosis) that change the level of GFAP (Verkhratsky & Nedergaard, 2018; Yang & Wang, 2015). The CSF GFAP levels were found to be higher in the ASD group than in controls of the same age range (Ahlsén et al., 1993; Rosengren et al., 1992). In contrast, similar S-100 protein concentrations were observed in both groups (Rosengren et al. 1992; Ahlsén et al. 1993).

To find the association between the CSF proteins and autistic traits in twins diagnosed with ASD and other neurodevelopmental disorders, a study measured 203 proteins in cerebrospinal fluid (n=86, ASD=19, neurotypical=41). The autistic traits correlated significantly with four CSF proteins (Smedler et al., 2021):

- C-C motif chemokine ligand 23 (CCL23) a chemokine active on immune cells like T lymphocytes and monocytes (Karan, 2021).
- Agouti-related protein (AGRP) synthesized in hypothalamic neurons that are involved in energy metabolism and appetite.
- 3. Chitinase-3-like protein 1 (CHI3L1) protein marker of inflammation.
- 4. Lipopolysaccharide-induced TNF-α factor (LITAF).

CCL23, AGRP, CHI3L1 correlated negatively, and LITAF correlated positively with autistic traits. Within twin pairs, no CSF protein concentrations were significantly associated with autistic traits. Proteins such as insulin-like growth factors, IGF-1, and IGF-2, are involved in the growth and development of the nervous system. In ASD, low CSF IGF-1 concentration was detected (Riikonen et al., 2006; Vanhala et al., 2001), but no difference was found in CSF IGF-2 levels (Riikonen et al., 2006).

Nerve growth factor (NGF), a protein similar to insulin (Andres & Bradshaw, 1980), is vital for the development and maintenance of sympathetic, sensory, and forebrain cholinergic neurons (Aloe et al., 2015). A study evaluating the CSF NGF concentrations found no significant differences in ASD compared to controls (Riikonen & Vanhala, 1999).

In the CSF of 3 children with ASD, including two siblings, succinyladenosine and succinyl-aminoimidazole carboxamide riboside purines were found (Jaeken & Van den Berghe, 1984), indicating a deficiency in the adenylosuccinate enzyme in the brain of at least a subgroup of individuals with genetically defined ASD (Jurecka et al., 2015). This enzyme is involved in the synthesis of purines and adenosine monophosphate.

Table 4 summarizes the results the relationship between the concentrations of amino acids/proteins in the CSF of individuals with ASD.

|                           | Age (study<br>group / control<br>group) | Study group<br>(ASD<br>participants)                      | Control group<br>(Non-ASD<br>participants) | Observations (in the study group)  |
|---------------------------|---|---|--|--|
| Khera et al.<br>2022      | 6 months / 6<br>months                  | 18 Wistar rats<br>(PPA-induced<br>rat model of<br>autism) | 12 Wistar rats                             | The level of CSF STAT3 protein is significantly elevated in the ASD model; long-term treatment with GST improved locomotor activity, memory, depressive behavior, and STAT3 level  |
| Smedler et al. *<br>2021  | 8 - 23 years /<br>8 - 23 years          | 19  | 41   | Twin study; in CSF across individuals, autistic traits correlated negatively with CCL23, AGRP, and CHI3L1, and positively with LITAF; within twin pairs, no CSF protein concentrations were significantly related with autistic traits |
| Runge et al.<br>2020      | 18 - 53 years /<br>18 - 61 years        | 36 (23 males, 13 females)                                 | 39 (6 males, 33<br>females)                | Increased protein concentrations and albumin<br>quotients in ASD   |
| Riikonen et al.<br>2006   | 1.9 - 15.9 years                        | 25 (20 males, 5<br>females)                               | 16 (8 males, 8<br>females)                 | IGF-1 concentration was significantly lower; head<br>circumferences correlated with IGF-1; no difference in<br>IGF-2 concentrations  |
| Vanhala et al.<br>2001    | 1.9 - 6.5 years /<br>1.9 - 5.5 years    | 11 (7 males, 4<br>females)                                | 11 (5 males, 6<br>females)                 | Levels of IGF-1 were significantly lower in ASD  |
| Riikonen et al<br>1999    | Mean age:<br>3.9 years /<br>4.3 years   | 14 (9 males, 5<br>females)                                | 24 (12 males, 12<br>females)               | No significant between-group difference in NGF in CSF  |
| Ahlsén et al.<br>1993     | 1.2 – 16 years /<br>1.3 – 18 years      | 47 (32 males, 15 females)                                 | 10 (7males, 3<br>females)                  | No difference in CSF S-100 protein; CSF GFAP in ASD was ~3x higher than in the control group   |
| Rosengren et al.<br>1992  | 1.2 - 16 years /<br>1.3 - 29 years      | 47 (32 males, 15 females)                                 | 13 (8 male, 5<br>females)                  | Higher CSF GFAP levels in ASD; similar S-100 protein<br>concentrations in both groups  |
| Jaeken and<br>Berghe 1984 | 1.6 - 3.7 years /                       | 3 (2 males, 1<br>female)                                  | 82   | CSF concentration of succinyladenosine and<br>succinylaminoimidazole carboxamide riboside were<br>significantly increased compared to controls   |
| Perry et al. **<br>1978   | 2 - 23 years / 2 -<br>15 years          | 16  | 23   | The mean concentration of ethanolamine in CSF was significantly elevated   |

### Table 4: Protein levels in CSF

Abbreviations- GFAP: Glial fibrillary acidic protein, BCAA: Branched-chain amino acids, IGF: Insulin-like growth factor, GST: Guggulsterone, NGF: Nerve growth factor; PPA: Propionic acid, CCL23: C-C motif chemokine ligand 23, AGRP: Agouti-related protein, LITAF: Lipopolysaccharide-induced TNF-α factor

\* ASD group (19/86); Control group (41/86); Males (55/86); Females (33/86)

\*\* ASD group (28/34); Males (19/28): CSF analyzed in ASD group (16/19)

### Monoamine neurotransmitter synthesis in ASD

Serotonin and the catecholamines dopamine, adrenaline, and noradrenaline are all important monoamine

neurotransmitters. These compounds are involved in many CNS functions, including motor control,

cognition, and emotion, and autonomic functions such as cardiovascular, respiratory, and gastrointestinal

control (Pons, 2010). The synthesis of serotonin and dopamine leads to the formation of 5-

hydroxyindolacetic acid (5-HIAA) and homovanillic acid (HVA), respectively (Lenchner JR, & Santos C.,

2023). Changes in the levels of 5-HIAA and HVA are associated with aggressive, impulsive, and

depressive behavior (Seo et al., 2008). In ASD, the CSF HVA was found to be increased (Gillberg et al.,

1983; Gillberg & Svennerholm, 1987; Komori et al., 1995; Toda et al., 2006), indicating a disturbance in dopamine synthesis. However, no significant difference was reported for 5-HIAA (Gillberg et al., 1983; Gillberg & Svennerholm, 1987; Komori et al., 1995). A later study found no significant difference in the mean HVA and mean 5-HIAA levels in the ASD and control groups (Narayan et al., 1993). A case report of one male child with ASD reported low 5-HIAA values (Adamsen et al., 2011). Extending this study to a larger ASD cohort (Adamsen et al., 2014), low 5-HIAA levels were found in 56% (26/46) participants. A 2020 study also reported reduced 5-HIAA concentration compared to controls in 34% (13/38) of the ASD participants (Ramaekers et al., 2020).

Tryptamines, such as the serotonin and melatonin neurotransmitters, are derived from the essential amino acid, tryptophan. Tryptamine is a trace amine that activates amine-associated receptors in the brain of mammals and regulates the activity of dopaminergic, serotonergic, and glutamatergic systems (Gainetdinov et al., 2018). Indoleacetic acid, a tryptamine metabolite, was found in typical concentration in the CSF of people with ASD (Anderson et al., 1988), suggesting that the central metabolism of tryptamine is likely normal in ASD. However, differences in the tryptophan metabolism were reported in ASD (Boccuto et al., 2013; Kałużna-Czaplińska et al., 2017) particularly in relation to the kynurenine pathway (Bryn et al., 2017; Carpita et al., 2023; Launay et al., 2023), but CSF analyses of metabolites generated by the kynurenine pathway are lacking.

Tetrahydrobiopterin (BH4) participates in the synthesis of monoamine neurotransmitters like dopamine, noradrenaline, and serotonin. This compound contributes to cellular metabolic pathways generating energy and protecting cells from inflammation (Eichwald et al., 2023). Studies have shown that ASD is related to the dysfunctional cerebral dopaminergic and serotoninergic systems (Nakamura et al., 2010). In the ASD group, the CSF BH4 levels were found to be significantly reduced compared to the control group (Tani et al. 1994). Low serotonin levels (5-HIAA) in CSF were unchanged when 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP) was used as an oral therapy (Komori et al., 1995), but half of the ASD group (7 out of 14) showed improvement in autistic traits. Secretin, a digestive hormone, was found to

17

promote the metabolism of serotonin and dopamine in the CNS and improved speech and sociability in

58% (7/12) of the participants with ASD whose CSF HVA level was elevated (Toda et al., 2006).

Table 5 summarizes the results related to monoamine neurotransmitters.

|                           | Age (study<br>group / control<br>group)  | Study group<br>(ASD<br>participants) | Control group<br>(Non-ASD<br>participants) | Observations (in the study group)  |
|---------------------------|--|--------------------------------------|--|--|
| Ramaekers et<br>al., 2020 | 3.6 – 18 years /<br>4.4 - 16 years       | 38 (31 males, 7<br>females)          | 24 (12 males, 12<br>females)               | Lowered 5HIAA in 34%; low 5HIAA to HVA ratio in 13%; low 5HIAA in 5% of ASD group  |
| Adamsen et al.<br>2014    | -  | 98                                   | CSF not analyzed                           | Low 5HIAA in CSF in 26 ASD participants  |
| Adamsen et al.<br>2011    | 4.5 years                                | 1 male                               | Case report                                | Low levels of the 5-HIAA in CSF  |
| Toda et al.<br>2006       | 4 - 16 years / 3<br>- 15 years           | 12 (8 males, 4<br>females)           | 17 (12 males, 5<br>females)                | Increased HVA (9 out of 12), 5-HIAA (7 out of 12),<br>R-BH4 levels (7 out of 12) in CSF and improved<br>autistic symptoms after secretin administration                                |
| Komori et al.<br>1995     | 2 - 9 years / 2.8<br>- 7 years           | 14 (7 males, 7<br>females)           | 18 (17 males, 1<br>female)                 | Increased level of mean HVA in ASD; no significant difference in mean 5-HIAA between ASD and control group; 7 participants showed improvements in autistic traits after R-THBP therapy |
| Tani et al.<br>1994       | 2.3 - 22.5 years<br>/ 0 - 12 years       | 20 (15 males, 5<br>females)          | 10 (7 males, 3<br>females)                 | $NH_2$ and R-BH4 levels in autistic children were reduced to 66.1% and 41.5% with respect to controls  |
| Anderson et al.<br>1988   | 5.2 - 10.8 years<br>/ 3.7 - 9 years      | 8 (7 males, 1<br>female)             | 10 (all males)                             | No difference in CSF levels of the tryptamine metabolite and IAA between the ASD and the control groups  |
| Narayan et al.<br>1993    | 2.9 - 8.5 years /<br>6.1 - 11.5 years    | 17 (12 males, 5<br>females)          | 15 (11 males, 4<br>females)                | No significant difference in the group means for 5HIAA and HVA levels in the autistic children and the control group   |
| Gillberg at al.<br>1987   | 1 - 16 years /<br>Mean age: 8.3<br>years | 25 (20 males, 5<br>females)          | 20 (15 males, 5<br>females)                | Increased mean HVA concentration; no significant difference in 5-HIAA, between ASD and control group   |
| Gillberg et al.<br>1983   | 3 - 14 years /<br>3 – 14 years           | 13 (10 males, 3<br>females)          | 13 (10 males, 3<br>females)                | Increased level of HVA in ASD; no significant difference in 5-HIAA between ASD and control group   |
|                           |  |                                      |  |  |

Table 5: Monoamine neurotransmitters in CSF

Abbreviations- 5HIAA: 5-hydroxyindolacetic acid, R-BH4: 6R-5,6,7,8-tetrahydrobiopterin, NH<sub>2</sub>: 7,8-dihydroneopterin, HVA: Homovanillic acid, IAA: Indoleacetic acid

#### Change in Oxytocin and Arginine vasopressin concentration in CSF

Oxytocin (OT) and arginine vasopressin (AVP) are nonapeptides that can cross the blood-brain barrier.

These peptides are mainly synthesized by neurons of the paraventricular nucleus (PVN) and supraoptic

nucleus (SON) of the hypothalamus (Higashida, 2016; Jin et al., 2007). Studies have demonstrated that AVP/OT neurons extend processes that cross the walls of the third ventricle to release these neuropeptides directly into the CSF (Grinevich et al., 2016; Taub et al., 2021). Both nonapeptides are found in the brains of males and females alike (Higashida et al., 2018; Neumann, 2008) and have an important role in neuronal function, social recognition, and social behavior in mammals, including humans (Higashida, 2016; Lukas & Neumann, 2013). Any change in the level of OT and AVP in CSF is indicative of impaired social behavior in mammals.

In the CSF, the effect of OT and AVP has mostly been studied on monkeys and rodent models (e.g., VPA-induced rat models of autism). In the VPA-induced model, the pregnant rats were injected with valproic acid (VPA). The offspring of these VPA-exposed mothers show behavioral, immunological, and physiological changes similar to those described in the autistic population (Liu et al., 2018).

CSF OT/AVP levels were altered in studies on monkeys and rat models of ASD. Low levels of OT in CSF (Dai et al., 2018; Gerasimenko et al., 2020) were found in adult VPA-induced rats and adult CD-157 knockout mice. The suggested therapy in the case of low OT concentration is to give oral nicotinamide riboside (Gerasimenko et al., 2020), a naturally occurring form of vitamin B3 (Conze et al., 2016), and aerosolized OT administration (Modi et al., 2014). These treatments provided a therapeutic effect on autistic-like behaviors in rodents and monkeys. The AVP studies established that CSF AVP concentrations correlate with social behaviors in monkeys (Oztan et al., 2021; Parker, 2022; Parker et al., 2018).

In OT/AVP studies on humans, the mean CSF AVP level was significantly lower in an all-male ASD group (Parker et al., 2018) as compared to controls. The mean CSF AVP concentration was found to be decreased in the ASD group (24 males, 12 females), irrespective of sexes (Oztan et al., 2018). Intranasal vasopressin treatment improved autism-like symptoms (Parker, 2022). Research reported that infants who were later diagnosed with ASD had very low mean neonatal CSF AVP concentrations (Oztan et al.,

19

2020). In an OT study with 0-3 months infants, no difference in mean neonatal CSF OT concentrations was found in infants later diagnosed with ASD compared to control.

Altogether, the studies support the use of OT and AVP as CSF biomarkers in studying ASD or social symptoms in autism. Table 6 comprises the ASD-related studies evaluating the concentration of these nonapeptides in the CSF.

|   | Age (study<br>group / control<br>group) | Study group (ASD participants)                           | Control group<br>(Non-ASD<br>participants)  | Observations (in the study group)  |  |
|---|---|--|---|--|--|
| Parker<br>2022  | Infant monkeys                          | 7 Rhesus monkeys (all males)                             | 7 Rhesus monkeys<br>(all males)             | Low CSF AVP concentration in ASD animal models   |  |
| Orton at al   |   | 75 Rhesus monk   | eys (all males)                             | Test-retest at 3 time points; low AVP levels;<br>monkeys with the lowest CSF AVP concentration<br>showed maximum social impairment   |  |
| 2021  | 1.3 - 6.3 years                         | 42-43 Rhesus mor   | ıkeys (all males)                           |  |  |
|   |   | 42-43 Rhesus mor   | keys (all males)                            |  |  |
| Wu et al.<br>2021   | Adolescent rats                         | VPA-induced rat model<br>12 (all males)                  | 15 (all males)                              | Rats exposed to VPA showed impaired<br>communication and repetitive behavior; reduced<br>number of AVP-ir cells in CSF   |  |
| Gerasimenko et<br>al. 2020  | Adult mice                              | CD-157 knockout mice (all males)                         | Wild-type mice (all males)                  | Low levels of OT in CSF; suggested treatment was the oral nicotinamide riboside  |  |
| Oztan et al. *<br>2020  | 0 - 3 months                            | 9  | 21  | Infants later diagnosed with ASD had significantly<br>lower mean neonatal CSF AVP concentrations<br>((9/9) as compared to those who were not later<br>diagnosed with ASD (17/21))<br>No difference in mean neonatal CSF OT<br>concentrations in infants (6/9) later diagnosed with<br>ASD compared to those who were not later<br>diagnosed with ASD (12/21) |  |
| Parker et al.<br>2018   | 1 - 5 years / 1 - 5<br>years            | 15 (male Rhesus<br>monkeys; low social)                  | 15 (male Rhesus<br>monkeys; high<br>social) | CSF AVP concentrations were correlated with sociability  |  |
|   | 5.3 - 19 years /<br>5.3 - 19.5 years    | 7 (all males)  | 7 (all males)                               | Significantly decreased CSF AVP concentrations in the ASD group  |  |
| Oztan et al.<br>2018  | 1.5 - 9 years                           | 36 (24 males, 12<br>females)                             | 36 (24 males, 12<br>females)                | Mean CSF AVP concentration was lower in the ASD group; no sex differences for AVP were found between the ASD and the control groups  |  |
| Dai et al. 2018   | adult rats                              | VPA induced rat model<br>(12 male and 15 female<br>rats) | 21 male and 18<br>female rats               | Reduced OT concentration in CSF of VPA rats  |  |
| Abbreviations- AVP: Arginine vasopressin, VPA: Valproic acid, OT: Oxytocin, ir: immunoreactive * ASD group (9/33); Control group (21/33); Females (3/33); Males (30/33) |   |  |   |  |  |

# Table 6: Concentration of OT and AVP in the CSF

# Beta-endorphin levels and gangliosides in CSF

β-Endorphins are one of five groups of naturally occurring opioid peptides found in neurons of the hypothalamus and the pituitary gland. In stressful situations, the pituitary gland releases beta-endorphins into the CSF (Gifford & Mahler, 2012). Beta endorphins are associated with emotions like hunger, thrill, pain, and cognition (Pilozzi et al., 2020). Studies found no significant difference in beta-endorphin levels between the ASD and the control group (Nagamitsu, 1993).

Brain gangliosides play an important role in synaptic transmission, and increased synaptic activity leads to the release of more gangliosides (Lekman et al., 1995). Four major gangliosides (GM1, GD1a, GD1b, and GT1b) were found to be increased in the CSF of the ASD group (Lekman et al., 1995; Nordin et al., 1998) Table 7 presents the results related to beta-endorphin and gangliosides in CSF of ASD.

|                          | Age (study<br>group /<br>control<br>group) | Study group<br>(ASD<br>participants) | Control group<br>(Non-ASD<br>participants) | Observations (in the study group)  |
|--------------------------|--|--------------------------------------|--|--|
| Nordin et al.<br>1998    | 1 - 22 years /<br>3 - 20 years             | 85 (65 males,<br>20 females)         | 29   | Significantly higher concentration of ganglioside GM1 in ASD group but no significant differences in ganglioside GDIa, GDIb, GTIb, and total ganglioside concentration |
| Nagamitsu et<br>al. 1997 | 2 - 6.4 years /<br>0 - 10.8<br>years       | 19 (17 males, 2<br>females)          | 23 (18 males, 5<br>females)                | No significant difference in $\beta$ -endorphin levels in ASD  |
| Lekman et al.<br>1995    | 9.0 ± 3.8<br>years / 8.8 ±<br>5.0 years    | 20 (12 males,<br>8 females)          | 25   | Brain gangliosides, GM1, GD1a, GD1b and GT1b, and their sum was increased in CSF of ASD group  |

Table 7: Concentration of beta-endorphins and gangliosides in the CSF

## Discussion

Our systematic review highlights the various changes in the composition of CSF associated with ASD. This systematic review provided clear evidence of increased cytokines (TNF-α, IFN-γ, IL-6, IL-8, MIP1β, NAP-2, IFN-γ), chemokines (MCP-1), lymphocytes, proteins, and growth factors in the CSF of the ASD population. ASD is also characterized by increased axial-CSF, GM1 ganglioside, and decreased folate, oxytocin, vasopressin, and serotonin (Fig 3a).

Different treatments were proposed to treat various deficiencies, such as nicotinamide riboside and aerosolized OT administration for low oxytocin, intranasal vasopressin (in animal models) for decreased AVP, folic acid supplements (Leucovorin) for folate deficiency, and secretin to promote dopamine and serotonin metabolism (Fig 3b).



(a)

(b)

Fig 3: Summary of the CSF properties in ASD and the suggested treatments. Panel (a) summarizes the CSF properties that are increased, decreased, and not significantly different from neurotypicals. Panel (b) highlights the treatments, as mentioned in the literature for different abnormal physiological traits of CSF.

These physiological characteristics of CSF in ASD led us to draw the conclusions discussed in the

following subsections.

# Neuroinflammation and active innate immune system

The increased presence of immune markers like cytokines, chemokines, and growth factors suggests an active innate immune system. Elevated CSF-TNF-α but normal blood serum- TNF-α indicates neuroinflammation. This unregulated inflammation can induce apoptosis or cells' death (Idriss & Naismith, 2000) and lead to inflammatory diseases (Van Loo & Bertrand, 2023).

# Extra-axial CSF increases between 6 months and 2 years of age in ASD

EA-CSF at a young age indicates a disruption in CSF absorption in the first year after birth when CSF

production is elevated (Murphy et al., 2020). The CSF increases till age 2 and then plateaus. This

elevation results in increased head circumference, third ventricle, and total CSF volume in ASD compared

to typically developing individuals. The increased EA-CSF constitutes a promising biomarker for the early detection of ASD.

#### Folate deficiency is linked to autistic characteristics

Folate + S-adenosylmethionine (SAMe) is crucial in regulating the production of THBP (or BH4), which is a co-factor in the synthesis of monoamine neurotransmitters (Bender et al., 2017). Thus, folate deficiency in ASD can be linked to low BH4 and impaired monoamine synthesis, low serotonin levels, and high HVA. Research indicates that these deficiencies result in sleep disorders and disrupted psychomotor, social, and verbal skills (Galli et al., 2022; Sasa et al., 2003; Yoshimura et al., 2020), all traits associated with ASD. These observations explain the use of R-TBHP and folic acid as treatments to improve concentration, motor skills, and verbal communication in ASD. Fig 4 shows the relationship of ASD with folate deficiency.



Fig 4: Folate deficiency linked to ASD characteristics.

#### Anxiety and sleep disorder in ASD are related to disturbed dopamine synthesis

Anxiety (Guerrera et al., 2022; van Steensel et al., 2011) and sleep disorders (Devnani & Hegde, 2015) are two of the most common comorbidities associated with ASD. Research has shown that the dopaminergic system is involved in anxiety disorder (Dong et al., 2020) and in the regulation of the sleep cycle (Oishi & Lazarus, 2017). CSF studies establish that high HVA levels are found in ASD, indicating a disturbance in dopamine synthesis. Thus, anxiety and sleep disorders in ASD can be attributed to defects in the dopamine pathway.

### Impulsive behavior is related to low serotonin levels

Self-injurious behaviors (SIB) and aggression are some of the severe symptoms associated with ASD (Gulsrud et al., 2018). Low serotonin (synthesized as 5-HIAA) is found to be responsible for aggression and self-harming behaviors (Linnoila & Virkkunen, 1992; Seo et al., 2008), suggesting an association between autistic traits like SIB and altered serotonin pathways.

#### Disturbed tyrosine (TYR) and tryptophan (TRP) pathway in ASD

The TYR and TRP are the two important metabolic pathways (Fig 5) modulating mood, behavior, cognition, and neuroimmune interaction (Aquili, 2020). These pathways lead to the formation of metabolites like HVA, quinolinic acid, IAA, and 5-HIAA (Galla et al., 2021). Elevated HVA, low 5-HIAA, and quinolinic acid, as well as altered BH4 and NH<sub>2</sub> levels indicate dysfunction in TYR and TRP pathways.



Fig 5: Tyrosine and Tryptophan pathways leading to the formation of HVA, Quinolinic acid, IAA, 5-HIAA

### Limitations

This systematic review has some limitations. Most importantly, we used only one database (Pubmed) for the search, and the studies were systematically screened and reviewed by only one author (VS). Also, no review protocol was prepared in writing and registered before conducting the review. However, the two authors regularly discussed the search and review procedures, the intermediate and final outcomes of

this process, and the problematic cases. The senior author (COR) selectively reviewed papers and areas with inconsistent or seemingly problematic results to ensure consensus between the two authors.

#### Gaps and future directions

We found several gaps in the literature. For example, treatments that showed promising results (Chez et al., 2012; Frye et al., 2013; Komori et al., 1995; Toda et al., 2006) were not tested on large cohorts. Also, only 12 out of 54 studies were carried out on ASD adults. Adult studies on ASD would help understand its progression in later life and the physiological changes taking place with age. Furthermore, the research findings in ASD adults may motivate customized healthcare services to improve their quality of life. Also, many papers did not highlight the results by sex despite studying both males and females (Pardo et al., 2017; Ramaekers et al., 2020; Runge et al., 2020; Vargas et al., 2005). The reporting of research observations by biological sex is crucial because of between-sex differences. A disorder like ASD may present different physiological traits in females than males, thus requiring different treatment and healthcare services.

With this systematic review, we found that the impairment of different inter-connected systems characterizes ASD, leading to a significant change in CSF traits. This conclusion confirms our hypothesis that the properties and composition of CSF are altered in ASD.

#### Acknowledgments

This work was supported by a pilot grant from the Carolina Autism & Neurodevelopment (CAN) Research Center (PI: Christian O'Reilly) at the University of South Carolina. We acknowledge that the funding agency has no role in study design, collection, analysis or interpretation of data, the writing of the report, and the decision to submit the article for publication.

#### **Author contributions**

Vandana Srivastava: review and screening of papers, writing original draft, visualization, investigation. Christian O'Reilly: methodology, writing- review and editing, supervision.

# **Conflict of interest**

The authors declare no conflict of interest.

# References

Adamsen, D., Meili, D., Blau, N., Thöny, B., & Ramaekers, V. (2011). Autism associated with low 5hydroxyindolacetic acid in CSF and the heterozygous SLC6A4 gene Gly56Ala plus 5-HTTLPR L/L promoter variants. *Molecular Genetics and Metabolism*, *102*(3), 368–373.

https://doi.org/10.1016/j.ymgme.2010.11.162

- Adamsen, D., Ramaekers, V., Ho, H. T., Britschgi, C., Rüfenacht, V., Meili, D., Bobrowski, E., Philippe, P., Nava, C., Van Maldergem, L., Bruggmann, R., Walitza, S., Wang, J., Grünblatt, E., & Thöny, B. (2014). Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. *Molecular Autism*, *5*, 43. https://doi.org/10.1186/2040-2392-5-43
- Adigun, Al-Dhahir. (2022). Anatomy, Head and Neck: Cerebrospinal Fluid (2023rd ed.). StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK459286/
- Ahlsén, G., Rosengren, L., Belfrage, M., Palm, A., Haglid, K., Hamberger, A., & Gillberg, C. (1993). Glial fibrillary acidic protein in the cerebrospinal fluid of children with autism and other neuropsychiatric disorders. *Biological Psychiatry*, *33*(10), 734–743.
   https://doi.org/10.1016/0006-3223(93)90124-v
- Aloe, L., Rocco, M. L., Balzamino, B. O., & Micera, A. (2015). Nerve Growth Factor: A Focus on Neuroscience and Therapy. *Current Neuropharmacology*, 13(3), 294–303. https://doi.org/10.2174/1570159x13666150403231920
- Anderson, G. M., Ross, D. L., Klykylo, W., Feibel, F. C., & Cohen, D. J. (1988). Cerebrospinal fluid
   indoleacetic acid in autistic subjects. *Journal of Autism and Developmental Disorders*, 18(2),
   259–262. https://doi.org/10.1007/BF02211951
- Andres, R. Y., & Bradshaw, R. A. (1980). NERVE GROWTH FACTOR. In *Biochemistry of Brain* (pp. 545– 562). Elsevier. https://doi.org/10.1016/B978-0-08-021345-3.50024-1

Andrews, F. M., Geiser, D. R., Sommardahl, C. S., Green, E. M., & Provenza, M. (1994). Albumin quotient, IgG concentration, and IgG index determinations in cerebrospinal fluid of neonatal foals. *American Journal of Veterinary Research*, 55(6), 741–745.

Aquili, L. (2020). The Role of Tryptophan and Tyrosine in Executive Function and Reward Processing. International Journal of Tryptophan Research: IJTR, 13, 1178646920964825. https://doi.org/10.1177/1178646920964825

Balashova, O. A., Visina, O., & Borodinsky, L. N. (2018). Folate action in nervous system development and disease. *Developmental Neurobiology*, 78(4), 391–402. https://doi.org/10.1002/dneu.22579

Bender, A., Hagan, K. E., & Kingston, N. (2017). The association of folate and depression: A metaanalysis. *Journal of Psychiatric Research*, 95, 9–18.

https://doi.org/10.1016/j.jpsychires.2017.07.019

- Boccuto, L., Chen, C.-F., Pittman, A. R., Skinner, C. D., McCartney, H. J., Jones, K., Bochner, B. R., Stevenson, R. E., & Schwartz, C. E. (2013). Decreased tryptophan metabolism in patients with autism spectrum disorders. *Molecular Autism*, 4(1), 16. https://doi.org/10.1186/2040-2392-4-16
- Bryn, V., Verkerk, R., Skjeldal, O. H., Saugstad, O. D., & Ormstad, H. (2017). Kynurenine Pathway in Autism Spectrum Disorders in Children. *Neuropsychobiology*, *76*(2), 82–88. https://doi.org/10.1159/000488157

Carpita, B., Nardi, B., Palego, L., Cremone, I. M., Massimetti, G., Carmassi, C., Betti, L., Giannaccini, G., & Dell'Osso, L. (2023). Kynurenine pathway and autism spectrum phenotypes: An investigation among adults with autism spectrum disorder and their first-degree relatives. *CNS Spectrums*, *28*(3), 374–385. https://doi.org/10.1017/S1092852922000840

CDC. (2022). Data & Statistics on Autism Spectrum Disorder. https://www.cdc.gov/ncbddd/autism/data.html

- Chez, M. G., Dowling, T., Patel, P. B., Khanna, P., & Kominsky, M. (2007). Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. *Pediatric Neurology*, *36*(6), 361–365. https://doi.org/10.1016/j.pediatrneurol.2007.01.012
- Chez, M. G., Low, R., Parise, C., & Donnel, T. (2012). Safety and observations in a pilot study of lenalidomide for treatment in autism. *Autism Research and Treatment*, 2012, 291601. https://doi.org/10.1155/2012/291601
- Conze, D. B., Crespo-Barreto, J., & Kruger, C. L. (2016). Safety assessment of nicotinamide riboside, a form of vitamin B3. *Human & Experimental Toxicology*, *35*(11), 1149–1160. https://doi.org/10.1177/0960327115626254
- Creasey, H., Rumsey, J. M., Schwartz, M., Duara, R., Rapoport, J. L., & Rapoport, S. I. (1986). Brain morphometry in autistic men as measured by volumetric computed tomography. *Archives of Neurology*, *43*(7), 669–672. https://doi.org/10.1001/archneur.1986.00520070027012
- Dai, Y.-C., Zhang, H.-F., Schön, M., Böckers, T. M., Han, S.-P., Han, J.-S., & Zhang, R. (2018). Neonatal Oxytocin Treatment Ameliorates Autistic-Like Behaviors and Oxytocin Deficiency in Valproic Acid-Induced Rat Model of Autism. *Frontiers in Cellular Neuroscience*, *12*, 355. https://doi.org/10.3389/fncel.2018.00355
- Denier, N., Steinberg, G., van Elst, L. T., & Bracht, T. (2022). The role of head circumference and cerebral volumes to phenotype male adults with autism spectrum disorder. *Brain and Behavior*, *12*(3), e2460. https://doi.org/10.1002/brb3.2460
- Devnani, P. A., & Hegde, A. U. (2015). Autism and sleep disorders. *Journal of Pediatric Neurosciences*, *10*(4), 304–307. https://doi.org/10.4103/1817-1745.174438
- DiStasio, M. M., Nagakura, I., Nadler, M. J., & Anderson, M. P. (2019). T lymphocytes and cytotoxic astrocyte blebs correlate across autism brains. *Annals of Neurology*, *86*(6), 885–898. https://doi.org/10.1002/ana.25610

- Dong, M.-X., Chen, G.-H., & Hu, L. (2020). Dopaminergic System Alteration in Anxiety and Compulsive Disorders: A Systematic Review of Neuroimaging Studies. *Frontiers in Neuroscience*, *14*, 608520. https://doi.org/10.3389/fnins.2020.608520
- Dziennis, S., & Alkayed, N. J. (2008). Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration. *Reviews in the Neurosciences*, *19*(4–5), 341–361. https://doi.org/10.1515/revneuro.2008.19.4-5.341
- Eichwald, T., Da Silva, L. D. B. D., Staats Pires, A. C. S., Niero, L., Schnorrenberger, E., Filho, C. C.,
  Espíndola, G., Huang, W.-L., Guillemin, G. J., Abdenur, J. E., & Latini, A. (2023).
  Tetrahydrobiopterin: Beyond Its Traditional Role as a Cofactor. *Antioxidants*, *12*(5), 1037.
  https://doi.org/10.3390/antiox12051037
- Faraci, F. M., Mayhan, W. G., & Heistad, D. D. (1990). Effect of vasopressin on production of cerebrospinal fluid: Possible role of vasopressin (V1)-receptors. *The American Journal of Physiology*, 258(1 Pt 2), R94-98. https://doi.org/10.1152/ajpregu.1990.258.1.R94
- Frye, R. E., Rossignol, D. A., Scahill, L., McDougle, C. J., Huberman, H., & Quadros, E. V. (2020). Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. *Seminars in Pediatric Neurology*, 35, 100835. https://doi.org/10.1016/j.spen.2020.100835
- Frye, R. E., Sequeira, J. M., Quadros, E. V., James, S. J., & Rossignol, D. A. (2013). Cerebral folate receptor autoantibodies in autism spectrum disorder. *Molecular Psychiatry*, 18(3), 369–381. https://doi.org/10.1038/mp.2011.175
- Gainetdinov, R. R., Hoener, M. C., & Berry, M. D. (2018). Trace Amines and Their Receptors. *Pharmacological Reviews*, *70*(3), 549–620. https://doi.org/10.1124/pr.117.015305
- Galla, Z., Rajda, C., Rácz, G., Grecsó, N., Baráth, Á., Vécsei, L., Bereczki, C., & Monostori, P. (2021). Simultaneous determination of 30 neurologically and metabolically important molecules: A sensitive and selective way to measure tyrosine and tryptophan pathway metabolites and other

biomarkers in human serum and cerebrospinal fluid. *Journal of Chromatography A*, 1635, 461775. https://doi.org/10.1016/j.chroma.2020.461775

- Galli, J., Loi, E., Visconti, L. M., Mattei, P., Eusebi, A., Calza, S., Fazzi, E., & ASD Collaborative Group.
   (2022). Sleep Disturbances in Children Affected by Autism Spectrum Disorder. *Frontiers in Psychiatry*, *13*, 736696. https://doi.org/10.3389/fpsyt.2022.736696
- Garic, D., McKinstry, R. C., Rutsohn, J., Slomowitz, R., Wolff, J., MacIntyre, L. C., Weisenfeld, L. A. H., Kim,
  S. H., Pandey, J., St John, T., Estes, A. M., Schultz, R. T., Hazlett, H. C., Dager, S. R., Botteron, K.
  N., Styner, M., Piven, J., Shen, M. D., & Infant Brain Imaging Study (IBIS) Network. (2023).
  Enlarged Perivascular Spaces in Infancy and Autism Diagnosis, Cerebrospinal Fluid Volume, and
  Later Sleep Problems. JAMA Network Open, 6(12), e2348341.
  https://doi.org/10.1001/jamanetworkopen.2023.48341
- Gerasimenko, M., Cherepanov, S. M., Furuhara, K., Lopatina, O., Salmina, A. B., Shabalova, A. A., Tsuji, C., Yokoyama, S., Ishihara, K., Brenner, C., & Higashida, H. (2020). Nicotinamide riboside supplementation corrects deficits in oxytocin, sociability and anxiety of CD157 mutants in a mouse model of autism spectrum disorder. *Scientific Reports*, *10*(1), 10035.

https://doi.org/10.1038/s41598-019-57236-7

- Gifford, A. H., & Mahler, D. A. (2012). Dyspnea. In *Clinical Respiratory Medicine* (pp. 250–260). Elsevier. https://doi.org/10.1016/B978-1-4557-0792-8.00019-2
- Gillberg, C., & Svennerholm, L. (1987). CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. *The British Journal of Psychiatry : The Journal of Mental Science*, 151, 89–94. https://doi.org/10.1192/bjp.151.1.89
- Gillberg, C., Svennerholm, L., & Hamilton-Hellberg, C. (1983). Childhood psychosis and monoamine metabolites in spinal fluid. *Journal of Autism and Developmental Disorders*, *13*(4), 383–396. https://doi.org/10.1007/BF01531587

Girault, J. B., Donovan, K., Hawks, Z., Talovic, M., Forsen, E., Elison, J. T., Shen, M. D., Swanson, M. R.,
Wolff, J. J., Kim, S. H., Nishino, T., Davis, S., Snyder, A. Z., Botteron, K. N., Estes, A. M., Dager, S.
R., Hazlett, H. C., Gerig, G., McKinstry, R., ... Piven, J. (2022). Infant Visual Brain Development and
Inherited Genetic Liability in Autism. *The American Journal of Psychiatry*, appiajp21101002.
https://doi.org/10.1176/appi.ajp.21101002

- Gomes, H. R. (2022). Cerebrospinal fluid analysis: Current diagnostic methods in central nervous system infectious diseases. *Arquivos De Neuro-Psiquiatria*, *80*(5 Suppl 1), 290–295. https://doi.org/10.1590/0004-282X-ANP-2022-S114
- Gordon, N. (2009). Cerebral folate deficiency. *Developmental Medicine & Child Neurology*, *51*(3), 180–182. https://doi.org/10.1111/j.1469-8749.2008.03185.x
- Grinevich, V., Knobloch-Bollmann, H. S., Eliava, M., Busnelli, M., & Chini, B. (2016). Assembling the Puzzle: Pathways of Oxytocin Signaling in the Brain. *Biological Psychiatry*, *79*(3), 155–164. https://doi.org/10.1016/j.biopsych.2015.04.013
- Guerrera, S., Pontillo, M., Tata, M. C., Di Vincenzo, C., Bellantoni, D., Napoli, E., Valeri, G., & Vicari, S. (2022). Anxiety in Autism Spectrum Disorder: Clinical Characteristics and the Role of the Family. *Brain Sciences*, *12*(12), 1597. https://doi.org/10.3390/brainsci12121597
- Gulsrud, A., Lin, C. E., Park, M. N., Hellemann, G., & McCracken, J. (2018). Self-injurious behaviours in children and adults with autism spectrum disorder (ASD). *Journal of Intellectual Disability Research*, *62*(12), 1030–1042. https://doi.org/10.1111/jir.12490
- Hallahan, B., Daly, E. M., McAlonan, G., Loth, E., Toal, F., O'Brien, F., Robertson, D., Hales, S., Murphy, C.,
  Murphy, K. C., & Murphy, D. G. M. (2009). Brain morphometry volume in autistic spectrum
  disorder: A magnetic resonance imaging study of adults. *Psychological Medicine*, *39*(2), 337–346. https://doi.org/10.1017/S0033291708003383

- Higashida, H. (2016). Somato-axodendritic release of oxytocin into the brain due to calcium amplification is essential for social memory. *The Journal of Physiological Sciences: JPS, 66*(4), 275–282. https://doi.org/10.1007/s12576-015-0425-0
- Higashida, H., Yuhi, T., Akther, S., Amina, S., Zhong, J., Liang, M., Nishimura, T., Liu, H.-X., & Lopatina, O.
  (2018). Oxytocin release via activation of TRPM2 and CD38 in the hypothalamus during
  hyperthermia in mice: Implication for autism spectrum disorder. *Neurochemistry International*, *119*, 42–48. https://doi.org/10.1016/j.neuint.2017.07.009
- Hrishi, A. P., & Sethuraman, M. (2019). Cerebrospinal Fluid (CSF) Analysis and Interpretation in Neurocritical Care for Acute Neurological Conditions. *Indian Journal of Critical Care Medicine: Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine, 23*(Suppl 2), S115– S119. https://doi.org/10.5005/jp-journals-10071-23187
- Hughes, H. K., Mills Ko, E., Rose, D., & Ashwood, P. (2018). Immune Dysfunction and Autoimmunity as
  Pathological Mechanisms in Autism Spectrum Disorders. *Frontiers in Cellular Neuroscience*, *12*, 405. https://doi.org/10.3389/fncel.2018.00405
- Idriss, H. T., & Naismith, J. H. (2000). TNF? And the TNF receptor superfamily: Structure-function relationship(s). *Microscopy Research and Technique*, *50*(3), 184–195. https://doi.org/10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H
- Jaeken, J., & Van den Berghe, G. (1984). An infantile autistic syndrome characterised by the presence of succinylpurines in body fluids. *Lancet (London, England)*, *2*(8411), 1058–1061.
- Jiang, N. M., Cowan, M., Moonah, S. N., & Petri, W. A. (2018). The Impact of Systemic Inflammation on Neurodevelopment. *Trends in Molecular Medicine*, 24(9), 794–804. https://doi.org/10.1016/j.molmed.2018.06.008

- Jiménez, A. J., Domínguez-Pinos, M.-D., Guerra, M. M., Fernández-Llebrez, P., & Pérez-Fígares, J.-M. (2014). Structure and function of the ependymal barrier and diseases associated with ependyma disruption. *Tissue Barriers*, *2*, e28426. https://doi.org/10.4161/tisb.28426
- Jin, D., Liu, H.-X., Hirai, H., Torashima, T., Nagai, T., Lopatina, O., Shnayder, N. A., Yamada, K., Noda, M., Seike, T., Fujita, K., Takasawa, S., Yokoyama, S., Koizumi, K., Shiraishi, Y., Tanaka, S., Hashii, M., Yoshihara, T., Higashida, K., ... Higashida, H. (2007). CD38 is critical for social behaviour by regulating oxytocin secretion. *Nature, 446*(7131), 41–45. https://doi.org/10.1038/nature05526
- Jurecka, A., Zikanova, M., Kmoch, S., & Tylki-Szymańska, A. (2015). Adenylosuccinate lyase deficiency. Journal of Inherited Metabolic Disease, 38(2), 231–242. https://doi.org/10.1007/s10545-014-9755-y
- Kałużna-Czaplińska, J., Jóźwik-Pruska, J., Chirumbolo, S., & Bjørklund, G. (2017). Tryptophan status in autism spectrum disorder and the influence of supplementation on its level. *Metabolic Brain Disease*, *32*(5), 1585–1593. https://doi.org/10.1007/s11011-017-0045-x
- Karan, D. (2021). CCL23 in Balancing the Act of Endoplasmic Reticulum Stress and Antitumor Immunity in Hepatocellular Carcinoma. *Frontiers in Oncology*, *11*, 727583. https://doi.org/10.3389/fonc.2021.727583
- Khera, R., Mehan, S., Bhalla, S., Kumar, S., Alshammari, A., Alharbi, M., & Sadhu, S. S. (2022).
   Guggulsterone Mediated JAK/STAT and PPAR-Gamma Modulation Prevents Neurobehavioral and Neurochemical Abnormalities in Propionic Acid-Induced Experimental Model of Autism. *Molecules*, 27(3), 889. https://doi.org/10.3390/molecules27030889

Komori, H., Matsuishi, T., Yamada, S., Yamashita, Y., Ohtaki, E., & Kato, H. (1995). Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism.
 *Journal of Autism and Developmental Disorders*, 25(2), 183–193.
 https://doi.org/10.1007/BF02178503

- Kuroda, H. (1983). *Gamma-aminobutyric acid (GABA) in cerebrospinal fluid.* (3). Okayama University Medical School. https://doi.org/10.18926/AMO/32437
- Launay, J.-M., Delorme, R., Pagan, C., Callebert, J., Leboyer, M., & Vodovar, N. (2023). Impact of IDO activation and alterations in the kynurenine pathway on hyperserotonemia, NAD+ production, and AhR activation in autism spectrum disorder. *Translational Psychiatry*, *13*(1), 380. https://doi.org/10.1038/s41398-023-02687-w
- Lekman, A., Skjeldal, O., Sponheim, E., & Svennerholm, L. (1995). Gangliosides in children with autism. *Acta Paediatrica (Oslo, Norway : 1992), 84*(7), 787–790. https://doi.org/10.1111/j.1651-2227.1995.tb13757.x
- Lenchner JR, & Santos C. (2023). *Biochemistry, 5 Hydroxyindoleacetic Acid*. https://www.ncbi.nlm.nih.gov/books/NBK551684/
- Lepennetier, G., Hracsko, Z., Unger, M., Van Griensven, M., Grummel, V., Krumbholz, M., Berthele, A., Hemmer, B., & Kowarik, M. C. (2019). Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. *Journal of Neuroinflammation*, *16*(1), 219. https://doi.org/10.1186/s12974-019-1601-6
- Linnoila, V. M., & Virkkunen, M. (1992). Aggression, suicidality, and serotonin. *The Journal of Clinical Psychiatry*, *53 Suppl*, 46–51.
- Liu, F., Horton-Sparks, K., Hull, V., Li, R. W., & Martínez-Cerdeño, V. (2018). The valproic acid rat model of autism presents with gut bacterial dysbiosis similar to that in human autism. *Molecular Autism*, *9*(1), 61. https://doi.org/10.1186/s13229-018-0251-3
- Lowe, T. L., Cohen, D. J., Miller, S., & Young, J. G. (1981). Folic acid and B12 in autism and neuropsychiatric disturbances of childhood. *Journal of the American Academy of Child Psychiatry*, 20(1), 104–111. https://doi.org/10.1016/s0002-7138(09)60720-2

- Lukas, M., & Neumann, I. D. (2013). Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. *Behavioural Brain Research*, 251, 85–94.
   https://doi.org/10.1016/j.bbr.2012.08.011
- Lun, M. P., Monuki, E. S., & Lehtinen, M. K. (2015). Development and functions of the choroid plexus– cerebrospinal fluid system. *Nature Reviews Neuroscience*, *16*(8), 445–457. https://doi.org/10.1038/nrn3921
- McAlonan, G. M., Cheung, V., Cheung, C., Suckling, J., Lam, G. Y., Tai, K. S., Yip, L., Murphy, D. G. M., & Chua, S. E. (2005). Mapping the brain in autism. A voxel-based MRI study of volumetric differences and intercorrelations in autism. *Brain : A Journal of Neurology*, *128*(Pt 2), 268–276. https://doi.org/10.1093/brain/awh332
- Modi, M. E., Connor-Stroud, F., Landgraf, R., Young, L. J., & Parr, L. A. (2014). Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques. *Psychoneuroendocrinology*, 45, 49–57. https://doi.org/10.1016/j.psyneuen.2014.02.011
- Moretti, P., Sahoo, T., Hyland, K., Bottiglieri, T., Peters, S., del Gaudio, D., Roa, B., Curry, S., Zhu, H., Finnell, R. H., Neul, J. L., Ramaekers, V. T., Blau, N., Bacino, C. A., Miller, G., & Scaglia, F. (2005). Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. *Neurology*, *64*(6), 1088–1090. https://doi.org/10.1212/01.WNL.0000154641.08211.B7
- Murphy, V. A., Shen, M. D., Kim, S. H., Cornea, E., Styner, M., & Gilmore, J. H. (2020). Extra-axial
   Cerebrospinal Fluid Relationships to Infant Brain Structure, Cognitive Development, and Risk for
   Schizophrenia. *Biological Psychiatry. Cognitive Neuroscience and Neuroimaging*, *5*(7), 651–659.
   https://doi.org/10.1016/j.bpsc.2020.03.008
- Nagamitsu, S. (1993). CSF beta-endorphin levels in pediatric neurologic disorders. *The Kurume Medical Journal*, 40(4), 233–241. https://doi.org/10.2739/kurumemedj.40.233

- Nakamura, K., Sekine, Y., Ouchi, Y., Tsujii, M., Yoshikawa, E., Futatsubashi, M., Tsuchiya, K. J., Sugihara, G., Iwata, Y., Suzuki, K., Matsuzaki, H., Suda, S., Sugiyama, T., Takei, N., & Mori, N. (2010). Brain Serotonin and Dopamine Transporter Bindings in Adults With High-Functioning Autism. *Archives of General Psychiatry*, *67*(1), 59. https://doi.org/10.1001/archgenpsychiatry.2009.137
- Narayan, M., Srinath, S., Anderson, G. M., & Meundi, D. B. (1993). Cerebrospinal fluid levels of
  homovanillic acid and 5-hydroxyindoleacetic acid in autism. *Biological Psychiatry*, *33*(8–9), 630–
  635. https://doi.org/10.1016/0006-3223(93)90102-j
- Neumann, I. D. (2008). Brain oxytocin: A key regulator of emotional and social behaviours in both females and males. *Journal of Neuroendocrinology*, 20(6), 858–865. https://doi.org/10.1111/j.1365-2826.2008.01726.x
- Nordin, V., Lekman, A., Johansson, M., Fredman, P., & Gillberg, C. (1998). Gangliosides in cerebrospinal fluid in children with autism spectrum disorders. *Developmental Medicine and Child Neurology*, 40(9), 587–594. https://doi.org/10.1111/j.1469-8749.1998.tb15423.x
- Oishi, Y., & Lazarus, M. (2017). The control of sleep and wakefulness by mesolimbic dopamine systems. *Neuroscience Research*, *118*, 66–73. https://doi.org/10.1016/j.neures.2017.04.008
- Oztan, O., Garner, J. P., Constantino, J. N., & Parker, K. J. (2020). Neonatal CSF vasopressin concentration predicts later medical record diagnoses of autism spectrum disorder. *Proceedings of the National Academy of Sciences of the United States of America*, *117*(19), 10609–10613. https://doi.org/10.1073/pnas.1919050117
- Oztan, O., Garner, J. P., Partap, S., Sherr, E. H., Hardan, A. Y., Farmer, C., Thurm, A., Swedo, S. E., & Parker, K. J. (2018). Cerebrospinal fluid vasopressin and symptom severity in children with autism. *Annals of Neurology*, *84*(4), 611–615. https://doi.org/10.1002/ana.25314
- Oztan, O., Talbot, C. F., Argilli, E., Maness, A. C., Simmons, S. M., Mohsin, N., Del Rosso, L. A., Garner, J. P., Sherr, E. H., Capitanio, J. P., & Parker, K. J. (2021). Autism-associated biomarkers: Test-retest

> reliability and relationship to quantitative social trait variation in rhesus monkeys. *Molecular Autism*, *12*(1), 50. https://doi.org/10.1186/s13229-021-00442-w

Parameswaran, N., & Patial, S. (2010). Tumor necrosis factor-α signaling in macrophages. *Critical Reviews in Eukaryotic Gene Expression*, 20(2), 87–103.

https://doi.org/10.1615/critreveukargeneexpr.v20.i2.10

- Pardo, C. A., Farmer, C. A., Thurm, A., Shebl, F. M., Ilieva, J., Kalra, S., & Swedo, S. (2017). Serum and cerebrospinal fluid immune mediators in children with autistic disorder: A longitudinal study. *Molecular Autism*, 8, 1. https://doi.org/10.1186/s13229-016-0115-7
- Parker, K. J. (2022). Leveraging a translational research approach to drive diagnostic and treatment advances for autism. *Molecular Psychiatry*, 27(6), 2650–2658. https://doi.org/10.1038/s41380-022-01532-8
- Parker, K. J., Garner, J. P., Oztan, O., Tarara, E. R., Li, J., Sclafani, V., Del Rosso, L. A., Chun, K., Berquist, S.
  W., Chez, M. G., Partap, S., Hardan, A. Y., Sherr, E. H., & Capitanio, J. P. (2018). Arginine
  vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates. *Science Translational Medicine*, *10*(439). https://doi.org/10.1126/scitranslmed.aam9100
- Perry, T. L. (1978). Amino compounds and organic acids in CSF, plasma, and urine of autistic children. Biological Psychiatry, 13(5), 575–586.
- Peterson, M., Prigge, M. B. D., Bigler, E. D., Zielinski, B., King, J. B., Lange, N., Alexander, A., Lainhart, J.
  E., & Nielsen, J. A. (2021). Evidence for normal extra-axial cerebrospinal fluid volume in autistic males from middle childhood to adulthood. *NeuroImage*, *240*, 118387. https://doi.org/10.1016/j.neuroimage.2021.118387
- Pilozzi, A., Carro, C., & Huang, X. (2020). Roles of β-Endorphin in Stress, Behavior, Neuroinflammation, and Brain Energy Metabolism. *International Journal of Molecular Sciences*, 22(1), 338. https://doi.org/10.3390/ijms22010338

- Pons, R. (2010). Aromatic Amino Acid Decarboxylase Deficiency. In *Encyclopedia of Movement Disorders* (pp. 64–68). Elsevier. https://doi.org/10.1016/B978-0-12-374105-9.00301-4
- Ramaekers, Sequeira, J. M., Thöny, B., & Quadros, E. V. (2020). Oxidative Stress, Folate Receptor Autoimmunity, and CSF Findings in Severe Infantile Autism. *Autism Research and Treatment*, 2020, 9095284. https://doi.org/10.1155/2020/9095284
- Ramaekers, V. T., Blau, N., Sequeira, J. M., Nassogne, M.-C., & Quadros, E. V. (2007). Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. *Neuropediatrics*, *38*(6), 276–281. https://doi.org/10.1055/s-2008-1065354
- Reiber, H. (1994). Flow rate of cerebrospinal fluid (CSF)—A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. *Journal of the Neurological Sciences*, *122*(2), 189–203. https://doi.org/10.1016/0022-510X(94)90298-4
- Reiber, H. (2003). Proteins in cerebrospinal fluid and blood: Barriers, CSF flow rate and source-related dynamics. *Restorative Neurology and Neuroscience*, *21*(3–4), 79–96.
- Riikonen, R., Makkonen, I., Vanhala, R., Turpeinen, U., Kuikka, J., & Kokki, H. (2006). Cerebrospinal fluid insulin-like growth factors IGF-1 and IGF-2 in infantile autism. *Developmental Medicine and Child Neurology*, *48*(9), 751–755. https://doi.org/10.1017/S0012162206001605
- Riikonen, R., & Vanhala, R. (1999). Levels of cerebrospinal fluid nerve-growth factor differ in infantile autism and Rett syndrome. *Developmental Medicine and Child Neurology*, 41(3), 148–152. https://doi.org/10.1017/s0012162299000328
- Rosengren, L. E., Ahlsén, G., Belfrage, M., Gillberg, C., Haglid, K. G., & Hamberger, A. (1992). A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of children. *Journal of Neuroscience Methods*, 44(2–3), 113–119. https://doi.org/10.1016/0165-0270(92)90004-w

Rossignol, D. A., & Frye, R. E. (2021). Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis. *Journal of Personalized Medicine*, *11*(11). https://doi.org/10.3390/jpm11111141

Runge, K., Tebartz van Elst, L., Maier, S., Nickel, K., Denzel, D., Matysik, M., Kuzior, H., Robinson, T., Blank, T., Dersch, R., Domschke, K., & Endres, D. (2020). Cerebrospinal Fluid Findings of 36 Adult Patients with Autism Spectrum Disorder. *Brain Sciences*, *10*(6). https://doi.org/10.3390/brainsci10060355

Sakka, L., Coll, G., & Chazal, J. (2011). Anatomy and physiology of cerebrospinal fluid. *European Annals of Otorhinolaryngology, Head and Neck Diseases, 128*(6), 309–316. https://doi.org/10.1016/j.anorl.2011.03.002

Sasa M., Nishi A., Kobayashi K., Sano H., Momiyama T., Uramura K., Yada T., Mori N., Suzuki K., & Minabe Y. (2003). Regulation of psychomotor functions by dopamine: Integration of various approaches. *Folia Pharmacologica Japonica*, *122*(3), 215–225. https://doi.org/10.1254/fpj.122.215

- Saurman, V., Margolis, K. G., & Luna, R. A. (2020). Autism Spectrum Disorder as a Brain-Gut-Microbiome Axis Disorder. *Digestive Diseases and Sciences*, 65(3), 818–828. https://doi.org/10.1007/s10620-020-06133-5
- Schilde, L. M., Kösters, S., Steinbach, S., Schork, K., Eisenacher, M., Galozzi, S., Turewicz, M., Barkovits,
  K., Mollenhauer, B., Marcus, K., & May, C. (2018). Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research. *PloS One*, *13*(11), e0206478. https://doi.org/10.1371/journal.pone.0206478
- Seo, D., Patrick, C. J., & Kennealy, P. J. (2008). Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. *Aggression and Violent Behavior*, 13(5), 383–395. https://doi.org/10.1016/j.avb.2008.06.003

- Shen, M. D. (2018). Cerebrospinal fluid and the early brain development of autism. *Journal of Neurodevelopmental Disorders*, *10*(1), 39. https://doi.org/10.1186/s11689-018-9256-7
- Shen, M. D., Nordahl, C. W., Li, D. D., Lee, A., Angkustsiri, K., Emerson, R. W., Rogers, S. J., Ozonoff, S., & Amaral, D. G. (2018). Extra-axial cerebrospinal fluid in high-risk and normal-risk children with autism aged 2-4 years: A case-control study. *The Lancet. Psychiatry*, 5(11), 895–904. https://doi.org/10.1016/S2215-0366(18)30294-3
- Shen, M. D., Nordahl, C. W., Young, G. S., Wootton-Gorges, S. L., Lee, A., Liston, S. E., Harrington, K. R., Ozonoff, S., & Amaral, D. G. (2013). Early brain enlargement and elevated extra-axial fluid in infants who develop autism spectrum disorder. *Brain: A Journal of Neurology*, *136*(Pt 9), 2825– 2835. https://doi.org/10.1093/brain/awt166
- Shen, M. D., & Piven, J. (2017). Brain and behavior development in autism from birth through infancy. Dialogues in Clinical Neuroscience, 19(4), 325–333.

https://doi.org/10.31887/DCNS.2017.19.4/mshen

- Shoffner, J., Trommer, B., Thurm, A., Farmer, C., Langley, W. A. 3rd, Soskey, L., Rodriguez, A. N., D'Souza,
  P., Spence, S. J., Hyland, K., & Swedo, S. E. (2016). CSF concentrations of 5methyltetrahydrofolate in a cohort of young children with autism. *Neurology*, *86*(24), 2258–
  2263. https://doi.org/10.1212/WNL.00000000002766
- Smedler, E., Kleppe, J., Neufeld, J., Lundin, K., Bölte, S., & Landén, M. (2021). Cerebrospinal fluid and serum protein markers in autism: A co-twin study. *Journal of Neurochemistry*, *158*(3), 798–806. https://doi.org/10.1111/jnc.15338
- Świderek-Matysiak, M., Oset, M., Domowicz, M., Galazka, G., Namiecińska, M., & Stasiołek, M. (2023). Cerebrospinal Fluid Biomarkers in Differential Diagnosis of Multiple Sclerosis and Systemic Inflammatory Diseases with Central Nervous System Involvement. *Biomedicines*, *11*(2), 425. https://doi.org/10.3390/biomedicines11020425

Tani, Y., Fernell, E., Watanabe, Y., Kanai, T., & Långström, B. (1994). Decrease in 6R-5,6,7,8 tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. *Neuroscience Letters*, 181(1–2), 169–172. https://doi.org/10.1016/0304-3940(94)90586-X

- Tate, D. F., Bigler, E. D., McMahon, W., & Lainhart, J. (2007). The relative contributions of brain, cerebrospinal fluid-filled structures and non-neural tissue volumes to occipital-frontal head circumference in subjects with autism. *Neuropediatrics*, 38(1), 18–24. https://doi.org/10.1055/s-2007-981450
- Taub, A., Carbajal, Y., Rimu, K., Holt, R., Yao, Y., Hernandez, A. L., LeSauter, J., & Silver, R. (2021).
   Arginine Vasopressin-Containing Neurons of the Suprachiasmatic Nucleus Project to CSF.
   *Eneuro*, 8(2), ENEURO.0363-20.2021. https://doi.org/10.1523/ENEURO.0363-20.2021
- Than, U. T. T., Nguyen, L. T., Nguyen, P. H., Nguyen, X.-H., Trinh, D. P., Hoang, D. H., Nguyen, P. A. T., & Dang, V. D. (2023). Inflammatory mediators drive neuroinflammation in autism spectrum disorder and cerebral palsy. *Scientific Reports*, *13*(1), 22587. https://doi.org/10.1038/s41598-023-49902-8
- Toda, Y., Mori, K., Hashimoto, T., Miyazaki, M., Nozaki, S., Watanabe, Y., Kuroda, Y., & Kagami, S. (2006). Administration of secretin for autism alters dopamine metabolism in the central nervous system. *Brain & Development*, *28*(2), 99–103. https://doi.org/10.1016/j.braindev.2005.05.005
- Van Loo, G., & Bertrand, M. J. M. (2023). Death by TNF: A road to inflammation. *Nature Reviews Immunology*, 23(5), 289–303. https://doi.org/10.1038/s41577-022-00792-3
- van Steensel, F. J. A., Bögels, S. M., & Perrin, S. (2011). Anxiety disorders in children and adolescents with autistic spectrum disorders: A meta-analysis. *Clinical Child and Family Psychology Review*, 14(3), 302–317. https://doi.org/10.1007/s10567-011-0097-0

- Vanhala, R., Turpeinen, U., & Riikonen, R. (2001). Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism. *Developmental Medicine and Child Neurology*, 43(9), 614–616. https://doi.org/10.1017/s0012162201001116
- Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005). Neuroglial activation and neuroinflammation in the brain of patients with autism. *Annals of Neurology*, 57(1), 67–81. https://doi.org/10.1002/ana.20315
- Verkhratsky, A., & Nedergaard, M. (2018). Physiology of Astroglia. *Physiological Reviews*, *98*(1), 239– 389. https://doi.org/10.1152/physrev.00042.2016
- Wichmann, T. O., Damkier, H. H., & Pedersen, M. (2021). A Brief Overview of the Cerebrospinal Fluid
   System and Its Implications for Brain and Spinal Cord Diseases. *Frontiers in Human Neuroscience*, 15, 737217. https://doi.org/10.3389/fnhum.2021.737217
- Xu, G., Snetselaar, L. G., Jing, J., Liu, B., Strathearn, L., & Bao, W. (2018). Association of Food Allergy and Other Allergic Conditions With Autism Spectrum Disorder in Children. JAMA Network Open, 1(2), e180279. https://doi.org/10.1001/jamanetworkopen.2018.0279
- Yang, Z., & Wang, K. K. W. (2015). Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker. *Trends in Neurosciences*, 38(6), 364–374. https://doi.org/10.1016/j.tins.2015.04.003
- Yoshimura, Y., Kikuchi, M., Saito, D. N., Hirosawa, T., Takahashi, T., Munesue, T., Kosaka, H., Naito, N.,
  Ouchi, Y., & Minabe, Y. (2020). Markers for the central serotonin system correlate to verbal ability and paralinguistic social voice processing in autism spectrum disorder. *Scientific Reports*, *10*(1), 14558. https://doi.org/10.1038/s41598-020-71254-w
- Young, J. G., Caparulo, B. K., Shaywitz, B. A., Johnson, W. T., & Cohen, D. J. (1977). Childhood autism. Cerebrospinal fluid examination and immunoglobulin levels. *Journal of the American Academy of Child Psychiatry*, *16*(1), 174–179. https://doi.org/10.1016/s0002-7138(09)61589-2

Zimmerman, A. W., Jyonouchi, H., Comi, A. M., Connors, S. L., Milstien, S., Varsou, A., & Heyes, M. P.

(2005). Cerebrospinal fluid and serum markers of inflammation in autism. Pediatric Neurology,

33(3), 195-201. https://doi.org/10.1016/j.pediatrneurol.2005.03.014